05

  • Deisseroth wins Fresenius Prize

    The Stanford psychiatrist, neuroscientist and bioengineer will be honored for three distinct contributions to the medical field: optogenetics, hydrogel-tissue chemistry and research into depression.

  • Data sifting finds hidden gene partnerships

    Targeting backup biological pathways often used by cancers can lead to more efficient drug development and less-toxic therapies. Stanford researchers have developed a new way to identify these pathways.

  • New vision research center established

    The philanthropic gift creates a center to help accelerate translational research, recruit faculty and train the next generation of leaders in vision science.

  • Integrating diverse data key to precision health

    At the Big Data in Biomedicine Conference, Dean Lloyd Minor said a key goal is tackling population health and disease prevention, not just waiting for illness to strike.

  • Psoriatic arthritis drug shows promise

    In a randomized clinical trial conducted by researchers at Stanford and more than 100 other medical centers, psoriatic arthritis patients given an injectable biologic drug for 24 weeks showed substantial improvement compared with patients who received placebo injections.

  • Preventing HIV among drug users

    As more people inject drugs like heroin, the risk of an HIV outbreak from shared needles increases. Stanford researchers examined four methods that could be cost-effective in preventing an outbreak.

  • How accurate are fitness devices?

    A Stanford inquiry into the accuracy of seven wristband activity monitors showed that six out of seven devices measured heart rate within 5 percent. None, however, measured energy expenditure well.

  • Stanford Medicine magazine on sex, gender and medicine

    The spring issue of the magazine highlights how sex and gender differences should be part of medical education, research and care. It includes a Q&A with Barbra Streisand on fighting gender discrimination in cardiovascular research and treatment.

  • A potential fast-acting treatment for OCD

    A Stanford psychiatrist is researching the effects of ketamine on the brains of patients with obsessive-compulsive disorder, hoping to determine why, in studies, the drug has provided relief from symptoms.

  • Ketamine used off-label to treat mental disorders

    As research shows that the hallucinogen is a potentially powerful treatment for intractable mental disorders, and academics continue to debate its safety, private clinics across the country offer the drug to patients now.


2021 ISSUE 2

Unlocking the secrets of the brain

COVID-19 Updates

Stanford Medicine is closely monitoring the outbreak of novel coronavirus (COVID-19). A dedicated page provides the latest information and developments related to the pandemic.